Novavax (NVAX) Equity Average (2011 - 2026)

Novavax's Equity Average history runs 16 years deep, the most recent figure standing at -$136.3 million for Q1 2026.

• In Q1 2026, Equity Average rose 61.04% year-over-year to -$136.3 million; the TTM figure through Mar 2026 stood at -$136.3 million (up 61.04% YoY), while the FY2025 annual figure was -$375.8 million, up 43.94% from the prior year.
• Equity Average was -$136.3 million for Q1 2026 at Novavax, up from -$142.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$19.0 million in Q2 2025 to a low of -$825.1 million in Q2 2023.
• Historically, Equity Average has averaged -$448.0 million across 5 years, with a median of -$491.5 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Equity Average slumped 1194.32% in 2022, then jumped 97.07% in 2025.
• A 5-year view of Equity Average shows it stood at -$600.0 million in 2022, then slipped by 16.27% to -$697.6 million in 2023, then grew by 17.56% to -$575.1 million in 2024, then jumped by 75.27% to -$142.2 million in 2025, then increased by 4.19% to -$136.3 million in 2026.
• The last three Equity Average figures came in at -$136.3 million (Q1 2026), -$142.2 million (Q4 2025), and -$59.5 million (Q3 2025), per Business Quant data.